title: Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
abstract: OBJECTIVE
  To evaluate change in quality of life (QoL) and symptoms in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in conditions of current clinical practice.
  
  
  METHODS
  Prospective, longitudinal, multicenter open-label study was carried out in urology outpatient clinics. Patients were ≥40 years of age with an International Prostate Symptom Score (IPSS) score ≥ 8. QoL and symptoms were measured at baseline and 6 months using the Benign Prostatic Hyperplasia Impact Index (BII) and the IPSS.
  
  
  RESULTS
  1713 patients were included for analysis. Mean (SD) IPSS and BII scores at baseline were 16.8 (5.4) and 6.8 (2.6), respectively. 8.9 % (n = 153) of study participants did not receive treatment (watchful waiting, WW), 70.3 % (n = 1204) were prescribed monotherapy (alpha-adrenergic blockers [AB]; phytotherapy [PT, of which 95.2 % was the hexanic extract of Serenoa repens, HESr]; or 5-alpha-reductase inhibitors [5ARI]), and 20.8 % (n = 356) received combined treatment (AB + 5ARI; AB + HESr; others). At 6 months, improvements in QoL were similar across the different medical treatment (MT) groups, both for monotherapy (AB: mean improvement [SD] of 2.4 points [2.4]; PT: 1.9 [2.4]; 5ARI: 2.5 [2.3]) and combined therapy (AB + 5ARI: 3.1 [2.9]; AB + PT: 3.1 [2.5]). There were no clinically significant differences between MT groups and all showed significant improvement over WW (p < 0.05). HESr showed similar efficacy to AB and 5ARI both as monotherapy and in combination with AB. Results on the IPSS were similar.
  
  
  CONCLUSIONS
  Improvements in QoL and symptoms were equivalent across the medical treatments most widely used in real-life practice to manage patients with moderate or severe LUTS. HESr showed an equivalent efficacy to AB and 5ARI with fewer side effects.
authors.affiliation: Urology Department, Hosp. Clínic Univ., IDIBAPS, Barcelona, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Alcaraz
authors.affiliation: Urology Department, Hosp. Univ. Puerta de Hierro, Majadahonda, Madrid, Spain.
authors.forename: Joaquín
authors.initials: J
authors.lastname: Carballido-Rodríguez
authors.affiliation: Urology Department, Hosp. Univ. Basurto, Bilbao, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Unda-Urzaiz
authors.affiliation: Urology Department, Hosp. Univ. Virgen del Rocío, Sevilla, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Medina-López
authors.affiliation: Urology Department, Hosp. Univ. La Fe, Valencia, Spain.
authors.forename: José L
authors.initials: JL
authors.lastname: Ruiz-Cerdá
authors.affiliation: Urology Department, Hosp. Univ. Puerto Real, Cádiz, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: Rodríguez-Rubio
authors.affiliation: Urology Department, Hosp. Univ. Parc Taulí Sabadell, Sabadell, Barcelona, Spain.
authors.forename: Darío
authors.initials: D
authors.lastname: García-Rojo
authors.affiliation: Llefià Primary Care Center, Badalona, Barcelona, Spain.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Brenes-Bermúdez
authors.affiliation: Urology Department, Complejo Hospitalario Universitario de Granada, Granada, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Cózar-Olmo
authors.affiliation: Urology Department, Hosp. Univ. Carlos Haya, Málaga, Spain.
authors.forename: Víctor
authors.initials: V
authors.lastname: Baena-González
authors.affiliation: Pierre Fabre Ibérica S.A., Ramon Trias Fargas, 7-11, 3º, 08005, Barcelona, Spain. jose.manasanch@pierre-fabre.com.
authors.forename: José
authors.initials: J
authors.lastname: Manasanch
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D004359:Drug Therapy, Combination; D000068538:Dutasteride / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D059411:Lower Urinary Tract Symptoms / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications / Q000628:therapy*; D053448:Prostatism / Q000209:etiology / Q000628:therapy*; D011788:Quality of Life; D028024:Serenoa; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin; D057832:Watchful Waiting
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D010936:Plant Extracts; C571812:Prostasan; D013449:Sulfonamides; D018120:Finasteride; D000077409:Tamsulosin; D000068538:Dutasteride
keywords: BII; BPH; IPSS; LUTS; Quality of life; Real-life practice
references.citation: Eur Rev Med Pharmacol Sci. 2012 May;16(5):569-74
references.pmid: 22774395
references.citation: Eur Urol. 2007 Jan;51(1):207-15; discussion 215-6
references.pmid: 16846678
references.citation: BJU Int. 2008 Nov;102 Suppl 2:8-12
references.pmid: 19032604
references.citation: World J Urol. 2012 Jun;30(3):419-26
references.pmid: 21892656
references.citation: BJU Int. 2009 Apr;103(7):919-26
references.pmid: 19239460
references.citation: Prostate Cancer Prostatic Dis. 2001;4(2):124-131
references.pmid: 12497050
references.citation: Prostate Cancer Prostatic Dis. 2000 Nov;3(3):195-199
references.pmid: 12497097
references.citation: Urology. 2002 Feb;59(2):245-50
references.pmid: 11834396
references.citation: Urology. 2000 Apr;55(4):540-6
references.pmid: 10736498
references.citation: Eur Urol. 2004 Jun;45(6):773-9; disucssion 779-80
references.pmid: 15149751
references.citation: Lancet. 1976 Jun 12;1(7972):1265-8
references.pmid: 73694
references.citation: Eur Urol. 2005 Jun;47(6):824-37
references.pmid: 15925080
references.citation: Actas Urol Esp. 2008 Feb;32(2):230-9
references.pmid: 18409474
references.citation: J Sex Med. 2014 Jun;11(6):1554-66
references.pmid: 24708055
references.citation: BJU Int. 2015 May;115(5):802-14
references.pmid: 25130493
references.citation: Int Urol Nephrol. 2001;32(3):423-32
references.pmid: 11583366
references.citation: Int J Mol Sci. 2013;14(7):14301-20
references.pmid: 23846725
references.citation: Prostate. 1998 Oct 1;37(2):77-83
references.pmid: 9759701
references.citation: BJU Int. 2012 Jun;109(12):1756-61
references.pmid: 22551330
references.citation: BJU Int. 2003 Oct;92(6):575-80
references.pmid: 14511037
references.citation: N Engl J Med. 2006 Feb 9;354(6):557-66
references.pmid: 16467543
references.citation: Pharmacology. 2008;82(4):270-5
references.pmid: 18849646
references.citation: BJU Int. 2012 Sep;110(6 Pt B):E301-7
references.pmid: 22520557
references.citation: BJU Int. 1999 Mar;83(4):410-5
references.pmid: 10210562
references.citation: Arch Esp Urol. 2002 Jan-Feb;55(1):97-105
references.pmid: 11957763
references.citation: Eur Urol. 2002 May;41(5):497-506; discussion 506-7
references.pmid: 12074791
references.citation: Urol Int. 2015;94(2):187-93
references.pmid: 25614155
references.citation: J Urol. 1995 Nov;154(5):1770-4
references.pmid: 7563343
references.citation: Eur Urol. 2013 Sep;64(3):493-501
references.pmid: 23465519
references.citation: BJU Int. 2004 Apr;93(6):751-6
references.pmid: 15049985
references.citation: Eur Urol. 2015 Sep;68(3):418-25
references.pmid: 25465970
references.citation: BJU Int. 2006 Nov;98(5):1019-24
references.pmid: 16945121
references.citation: Prostate. 1999 Sep 1;40(4):232-41
references.pmid: 10420151
references.citation: BJU Int. 2008 Apr;101(7):847-52
references.pmid: 18321317
references.citation: Eur Urol. 2011 Nov;60(5):1105-13
references.pmid: 21871706
references.citation: BJU Int. 2008 Sep;102(8):981-6
references.pmid: 18549433
references.citation: Int Urol Nephrol. 2014 Apr;46(4):695-701
references.pmid: 24136187
references.citation: Med Care. 1995 Apr;33(4 Suppl):AS145-55
references.pmid: 7536866
references.citation: Curr Opin Urol. 2006 Jan;16(1):1-4
references.pmid: 16385193
references.citation: N Engl J Med. 2003 Dec 18;349(25):2387-98
references.pmid: 14681504
references.citation: Int Urol Nephrol. 2007;39(3):879-86
references.pmid: 17203353
references.citation: Eur Urol. 2010 Jan;57(1):123-31
references.pmid: 19825505
references.citation: Prostate. 1996 Oct;29(4):231-40; discussion 241-2
references.pmid: 8876706
references.citation: Prostate Cancer Prostatic Dis. 2004;7(3):195-200
references.pmid: 15289814
references.citation: Urology. 2014 Mar;83(3):539-43
references.pmid: 24246318
references.citation: JAMA. 2011 Sep 28;306(12):1344-51
references.pmid: 21954478
references.citation: BJU Int. 2006 Jul;98(1):83-8
references.pmid: 16831149
references.citation: Urology. 1998 Oct;52(4):614-20
references.pmid: 9763080